| Preferred Name |
Silmitasertib |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C98054 |
| CAS_Registry |
1009820-21-6 |
| Chemical_Formula |
C19H12ClN3O2 |
| code |
C98054 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923 |
| Contributing_Source |
GDC FDA |
| DEFINITION |
An orally bioavailable small-molecule inhibitor of the enzyme casein kinase II (CK2), with potential antineoplastic, anti-viral and immunomodulatory activities. Upon oral administration, silmitasertib selectively binds to and inhibits the activity of CK2. This may inhibit proliferation of CK2-expressing tumor cells, and may also inhibit the replication of severe acute respiratory syndrome coronavirus-2 (SARS-COV-2). In addition, this may restore normal host cell cytokine regulation, prevent cytokine storm and suppress the hyperactivation of the innate immune system. CK2, a protein kinase often overexpressed in a variety of cancer cell types, appears to be correlated with malignant transformation, tumor growth and survival. CK2 regulates a diverse array of pro-survival cellular processes including epidermal growth factor receptor (EGFR) signaling, PI3K/AKT/mTOR signaling, hedgehog (Hh) signaling, Hsp90 machinery, hypoxia, and interleukin (IL)-6 expression. CK2 also regulates the activity of XRCC1 and MDC1, two mediator/adaptor proteins that are essential for DNA repair. CK2 is upregulated by SARS-COV-2 and is associated with SARS-COV-2 viral replication and the development of cytokine storm. |
| FDA_UNII_Code |
C6RWP0N0L2 |
| FULL_SYN |
CX 4945 5-((3-chlorophenyl)amino)-benzo(c)-2,6-naphthyridine-8-carboxylic Acid CX-4945 SILMITASERTIB CX4945 Silmitasertib |
| Has_Salt_Form | |
| Has_Target | |
| label |
Silmitasertib |
| Preferred_Name |
Silmitasertib |
| prefixIRI |
Thesaurus:C98054 |
| prefLabel |
Silmitasertib |
| Semantic_Type |
Pharmacologic Substance |
| UMLS_CUI |
C2974252 |
| subClassOf |
| Delete | Mapping To | Ontology | Source |
|---|---|---|---|
| http://purl.bioontology.org/ontology/MESH/C555142 | Medical Subject Headings / 医学主题词表 | LOOM |